PAS
CTMX icon

Point72 Asia (Singapore)’s CytomX Therapeutics CTMX Stock Holding History

Point72 Asia (Singapore)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-87,226
Closed -$190K – 1124
2024
Q1 		$190K Buy
+87,226
New +$161K 0.05% 450

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Point72 Asia (Singapore)'s CTMX Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 87,226 shares — an estimated $190K sold.

Point72 Asia (Singapore) first reported a position in CTMX in Q1 2024 and held it in 1 quarter. The position peaked at $190K in Q1 2024. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 87,226 CytomX Therapeutics shares in Q2 2024, an estimated $190K.
  • Point72 Asia (Singapore) first reported a position in CytomX Therapeutics in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s CytomX Therapeutics position peaked at $190K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.